Cellenkos Wins FDA Fast Track for CK0803 in ALS
Houston, Texas, Aug 27, 2026 Cellenkos, Inc. has received FDA Fast Track designation for CK0803, an investigational allogeneic, cord...
Cellenkos
Advertisement
Cellenkos Secures FDA IND Clearance for CK0802 in GVHD Trial
HOUSTON, TEXAS, May 04, 2026 Cellenkos has announced that the U.S. Food and Drug Administration (FDA) has granted Investigational...
Cellenkos Wins FDA Clearance for CK0801 Phase 2 Trial
HOUSTON, TEXAS, April 27, 2026 Cellenkos Inc. has received U.S. Food and Drug Administration (FDA) clearance to initiate a...
FDA Grants Orphan Drug Status to Cellenkos’ CK0803 for ALS Treatment
HOUSTON, Oct. 20, 2025 – The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to...
Advertisement
